Buchumschlag

Risk of Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Kanghee Park, Hye Won Lee, Euichang Kim, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Changhoon Yoo, Baek‐Yeol Ryoo, Seungbong Han, Jonggi Choi
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply
von: Jonggi Choi
Veröffentlicht: (2025)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
von: Subin Heo, et al.
Veröffentlicht: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
von: Jiwon Yang, et al.
Veröffentlicht: (2025)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
von: Dong Hyun Kim, et al.
Veröffentlicht: (2025)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
von: Sung Won Chung, et al.
Veröffentlicht: (2024)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply
von: Subin Heo, et al.
Veröffentlicht: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
von: Dong Hyun Kim, et al.
Veröffentlicht: (2025)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
von: Dong Hyun Kim, et al.
Veröffentlicht: (2025)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
von: Hyeyeon Hong, et al.
Veröffentlicht: (2024)

Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort
von: Najib Ben Khaled, et al.
Veröffentlicht: (2025)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
von: Yewan Park, et al.
Veröffentlicht: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
von: Hye Won Lee, et al.
Veröffentlicht: (2024)

Clinical Course and Prognosis of Long‐Term Survivors of Hepatocellular Carcinoma
von: Soon Sun Kim, et al.
Veröffentlicht: (2025)

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort
von: Seogsong Jeong, et al.
Veröffentlicht: (2026)

Robust Predictive Performance of the SALT‐M Score for Clinical Outcomes in Asian Patients With Acute‐on‐Chronic Liver Failure
von: Kunhee Kim, et al.
Veröffentlicht: (2024)

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs . Authors' Reply
von: Min Joo Yoon, et al.
Veröffentlicht: (2026)

P‐ CAB vs. PPI for Upper Gastrointestinal Bleeding Prevention in Patients With Atherothrombotic Disease on Antithrombotic Therapy: A CDM Cohort Study
von: Min Joo Yoon, et al.
Veröffentlicht: (2026)

Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicenter Real‐World Study
von: Yi Xiang, et al.
Veröffentlicht: (2025)

Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability
von: Jiwon Yang, et al.
Veröffentlicht: (2024)

Editorial: Flipping the Script—Higher Risk of Hepatocellular Carcinoma With Tenofovir Compared to Entecavir in a French Population‐Based Cohort
von: Ariel Lee, et al.
Veröffentlicht: (2025)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
von: Darren Jun Hao Tan, et al.
Veröffentlicht: (2024)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
von: Silvia Nardelli, et al.
Veröffentlicht: (2025)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
von: Kuo‐Cheng Wu, et al.
Veröffentlicht: (2024)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
von: Kyuwon Kim, et al.
Veröffentlicht: (2024)

Antiplatelet Resumption Timing in Post‐Percutaneous Coronary Intervention Gastrointestinal Bleeding
von: Darrick K. Li, et al.
Veröffentlicht: (2026)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
von: Jiaqi Shen, et al.
Veröffentlicht: (2026)

Letter: Post‐Banding Ulcer Bleeding Is More Common With Urgent EBL and Renal Dysfunction
von: Jurij Maurer, et al.
Veröffentlicht: (2026)

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding
von: Xiaoqing Yang, et al.
Veröffentlicht: (2026)

Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC
von: Jiwon Yang, et al.
Veröffentlicht: (2024)

Improving the hepatitis C virus care cascade with the in‐hospital Reflex tEsting ALarm‐C (REAL‐C) model
von: Jonggi Choi, et al.
Veröffentlicht: (2024)

Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
von: Lauren Holtslander, et al.
Veröffentlicht: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
von: Shuaibing Ying, et al.
Veröffentlicht: (2026)

Editorial: Prevention of Upper GI Bleeding in Users of Anti‐Thrombotic Drugs—P‐ CABs Versus PPIs
von: Ali S. Taha
Veröffentlicht: (2026)

Editorial: Direct‐Acting Agents and Risk of Hepatocellular Carcinoma—The End of Controversy
von: Vincent Haghnejad, et al.
Veröffentlicht: (2025)

Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
von: Austin Haynesworth, et al.
Veröffentlicht: (2024)

Editorial: Genotyping for Hepatocellular Carcinoma Risk Stratification in the General Population. Authors' Reply
von: Daniel Q. Huang, et al.
Veröffentlicht: (2026)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
von: Romeo Kuo‐Cheng Wu, et al.
Veröffentlicht: (2025)

Editorial: An Important Step Towards Mastering Metabolic Dysfunction‐Associated Steatohepatitis‐Targeted Therapy in Diabetes
von: Johnny Yau‐Cheung Chang, et al.
Veröffentlicht: (2025)